Welcome to our dedicated page for NEPHROS SEC filings (Ticker: NEPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nephros Inc. filings document formal disclosures for a water technology company selling filtration solutions to medical and commercial markets. Recent 8-K reports furnish operating results and financial condition updates, Regulation FD presentations, and material event disclosures tied to the company's product, service, and education strategy.
The filing record also includes a material definitive agreement with Medica S.p.A. covering license and supply arrangements for filtration products based on Medisulfone ultrafiltration technology. These disclosures describe contractual rights, supply obligations, product commercialization arrangements, and related public-company reporting matters.
NEPHROS INC (NEPH) had insider activity reported by entities associated with Wexford Capital LP. On 2026-08-18, Wexford Capital exercised stock options to purchase 3,765 shares of common stock at an exercise price of $3.60 per share through a cashless exercise, with a portion of the option shares withheld to satisfy the exercise price. This resulted in the acquisition of 812 shares of common stock, bringing Wexford Capital’s direct common stock holdings to 56,872 shares and leaving 36,198 stock options outstanding, expiring on August 24, 2026. Wexford GP LLC, Charles E. Davidson and Joseph M. Jacobs may be deemed controlling persons of Wexford Capital and disclaim beneficial ownership except to the extent of any pecuniary interests. The transactions were not reported as made under a Rule 10b5-1 trading plan.
Nephros Inc. director Arthur H. Amron received 2,418 shares of Common Stock on 2026-08-12 as a grant in lieu of cash fees for board service, bringing his direct Common Stock holdings to 140,874 shares. He also holds stock options to acquire 7,323 shares of Common Stock at an exercise price of $2.14 per share that are fully vested, and additional options for 7,050 shares at an exercise price of $1.47 per share that vest in three equal installments of 2,350 shares on 1/1/25, 1/1/26 and 1/1/27.
Nephros, Inc. reported stronger results for the quarter and six months ended June 30, 2026. Q2 net revenue rose 36% to $6.0 million, and six‑month net revenue grew 21% to $11.2 million, driven mainly by programmatic product growth, commercial products, and higher service revenue.
Q2 net income increased to $1.2 million from $0.2 million a year earlier, while six‑month net income rose to $1.3 million from $0.8 million. Q2 gross margin expanded to 67%, aided by a $0.6 million IEEPA tariff refund recorded as a reduction of cost of goods sold; underlying costs faced pressure from a weaker U.S. dollar, higher shipping, and mix shift toward lower‑margin services and commercial offerings.
Cash and cash equivalents were $4.7 million with working capital of $10.3 million, and management believes existing cash and projected cash flows will fund operations for at least 12 months, despite $1.0 million of operating cash outflows in the first half from increases in receivables and inventory. The company highlights customer and supplier concentration, significant minimum purchase commitments under its Medica license and supply agreement, ongoing tariff headwinds, and discloses a material weakness in internal control over financial reporting as of June 30, 2026.
Nephros, Inc. reported strong results for the quarter and six months ended June 30, 2026. Second-quarter net revenue reached a record $6.0 million, up 36% from $4.4 million a year earlier, driven mainly by 27% growth in core programmatic product revenue and nearly tripled service revenue. Net income for the quarter rose to $1.2 million from $0.2 million, and Adjusted EBITDA increased to $1.3 million from $0.4 million.
Quarterly gross margin improved to 67% from 63%, helped by recognition of an approximately $0.6 million tariff refund under the International Emergency Economic Powers Act, recorded as a receivable and reduction of cost of goods sold. For the first half of 2026, net revenue was $11.2 million versus $9.3 million, and net income was $1.3 million versus $0.8 million. As of June 30, 2026, Nephros held about $4.7 million in cash and cash equivalents and remained debt free, with management highlighting its expanding recurring revenue base, growing service platform, and newer product offerings as key growth drivers.
Nephros Inc. director Arthur H. Amron reported an equity grant of 3,574 shares of Common Stock, issued in lieu of cash fees for board service. The shares were granted at no cash cost, bringing his direct Common Stock holdings to 138,456 shares after the transaction.
He also reports outstanding stock options to purchase 7,050 shares of Common Stock at an exercise price of $1.47 per share expiring on January 1, 2035, and options on 7,323 shares at $2.14 per share expiring on May 14, 2034. Footnotes indicate these options vest in equal annual installments on specified future dates.
Nephros, Inc. furnished an updated 2026 Corporate Presentation on its website on June 12, 2026, and attached it as Exhibit 99.1 to a current report. The presentation is provided as public information but is designated as “furnished,” meaning it is not treated as formally filed under the securities laws or automatically incorporated into other registration or reporting documents.
Nephros, Inc. reported first-quarter 2026 net revenue of $5.2 million, up 7% from $4.9 million a year earlier, driven by 23% growth in core programmatic product revenue and partially offset by lower emergency response sales. Net income declined to $140,000 from $558,000, and gross margin fell to 57% from 65%, mainly due to U.S. tariffs, a stronger Euro increasing product costs, and a higher mix of lower-margin commercial revenue. Adjusted EBITDA was $206,000, down from $667,000. As of March 31, 2026, Nephros held $4.0 million in cash and cash equivalents, remained debt free, and reported total assets of $13.8 million.
Nephros, Inc. reported net income of $140,000 for the three months ended March 31, 2026, down from $558,000 a year earlier, as profitability was pressured by higher costs. Total net revenue rose to $5.2 million from $4.9 million, driven mainly by programmatic product sales, while emergency response revenue declined.
Gross margin narrowed to 57% from 65%, primarily due to higher product costs tied to a weaker U.S. dollar versus the Euro, tariffs implemented in May 2025, and a higher mix of lower-margin commercial revenues. Operating income fell to $97,000 from $566,000.
Cash used in operating activities was $1.7 million in the quarter, compared with $0.3 million provided a year earlier, mainly reflecting higher accounts receivable and inventory and lower accrued expenses. Cash and cash equivalents were $4.0 million as of March 31, 2026, and working capital was $9.0 million.
The company continues to carry an accumulated deficit of about $143 million but remained profitable for both Q1 2026 and full-year 2025 and believes existing cash will fund its operating plan for at least the next 12 months. Nephros also applied in April 2026 for a potential refund of $646,698 in tariffs paid under now-invalidated IEEPA-based programs, though no asset or gain has been recorded.
Nephros maintains an exclusive license and supply agreement with Medica S.p.A. that includes minimum annual purchase commitments through 2030; failure to meet these euro-denominated purchase levels could allow Medica to terminate the agreement. The company also continues to remediate a previously identified material weakness in internal control over revenue recognition for contracts with multiple performance obligations, although management believes the financial statements are fairly presented.
Nephros, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add previously omitted Part III information and update the exhibit list. The amendment details board composition, executive and director pay, equity awards, major shareholders, related-party oversight and auditor fees, but does not change the original financial statements or reflect events after the original filing.
Nephros, Inc. furnished a current report to highlight that it has posted an updated 2026 Corporate Presentation on its corporate website. The presentation is provided as Exhibit 99.1 and is being shared as a Regulation FD disclosure, meaning it is intended to give the market broadly equal access to the same information.
The company notes that the presentation and related disclosure are considered "furnished" rather than "filed" under securities laws, which affects how they may be used in securities law liability and future SEC filings. The report is signed on behalf of Nephros by Chief Financial Officer Judy Krandel.